Related Experiment Video
Updated: Aug 17, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
Who is hematopoietic stem cell: CD34+ or CD34-?
1Department of Experimental Hematology, Beijing Institute of Radiation Medicine, People's Republic of China. peixt@nic.bmi.ac.cn
Hematopoietic stem cells (HSC) possess multipotentiality, enabling them to self-renew and also to produce mature blood cells, such as erythrocytes, leukocytes, platelets, and lymphocytes. CD34 is a marker of human HSC, and all colony-forming activity of human bone marrow (BM) cells is found in the CD34+ fraction. Clinical transplantation studies that used enriched CD34+ BM cells indicated the presence of HSC with long-term BM reconstitutional ability within this fraction. But recent studies in NOD/SCID mice, rhesus monkeys, and human/sheep competitive engraftment models have provided evidence for the presence of a rare cell population that contains progenitors capable of producing CD34+ cells in vitro. These progenitors are highly enriched in HSC and have competitive long-term in vivo repopulating potential devoid of both CD34 and lineage-marker expression. These new findings add to the growing evidence that some stem cells in the BM do not express the CD34 marker, which is currently used to select stem cells for transplantation.
Hematopoietic stem cells (HSC) possess multipotentiality, enabling them to self-renew and also to produce mature blood cells, such as erythrocytes, leukocytes, platelets, and lymphocytes. CD34 is a marker of human HSC, and all colony-forming activity of human bone marrow (BM) cells is found in the CD34+ fraction. Clinical transplantation studies that used enriched CD34+ BM cells indicated the presence of HSC with long-term BM reconstitutional ability within this fraction. But recent studies in NOD/SCID mice, rhesus monkeys, and human/sheep competitive engraftment models have provided evidence for the presence of a rare cell population that contains progenitors capable of producing CD34+ cells in vitro. These progenitors are highly enriched in HSC and have competitive long-term in vivo repopulating potential devoid of both CD34 and lineage-marker expression. These new findings add to the growing evidence that some stem cells in the BM do not express the CD34 marker, which is currently used to select stem cells for transplantation.
Related Concept Videos
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Production of Formed Elements
Most HSCs commit to...

